Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
GSK’s shares have opened higher after sales and profits for the first quarter exceeded expectations.
GSK’s shares rose at the opening of trading after the company reported that its Q1 revenue and profits had exceeded expectations, driven by the success of its Shingrix shingles vaccine.
hVIVO PLC FDA Breakthrough and Fast Track for US biotech
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US
Activation of First Clinical Trial Site in the U.S
N4 Pharma PLC (AIM:N4P) siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing
hVIVO PLC (AIM:HVO) Final results
Transformational year with record EBITDA underlining strong operational delivery
Avacta Group PLC (AIM:AVCT) Preliminary Results for the year ended 31 December 2022
A period of continued significant progress
ANGLE reports that its order book remains robust, citing 2022 as a year of significant progress.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
Avacta Group PLC (AIM:AVCT) AVA3996 data poster presented at AACR
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Intelligent Ultrasound Group (AIM:IUG) is still at an early stage, but prospects are bright
If you were to walk into the imaging department of any NHS hospital, what would you see? A room filled with patients waiting for X-rays, ultrasounds, and other diagnostic procedures.